Is this follow‑up note appropriate for a 17‑year‑old male with attention‑deficit/hyperactivity disorder (ADHD) and comorbid autism spectrum disorder (ASD) who is currently taking dextroamphetamine‑amphetamine extended‑release 30 mg each morning, dextroamphetamine‑amphetamine immediate‑release 5 mg at noon, and clonidine 0.1 mg twice daily, given the reported modest improvement in focus and impulsivity, good appetite and sleep, no side effects, and ongoing behavioral concerns at school?

This follow-up note is inadequate and requires significant revision to meet standard-of-care documentation for a 17-year-old with ADHD and comorbid ASD on controlled substances.

Critical Documentation Deficiencies

The note lacks essential monitoring parameters and clinical decision-making justification required for stimulant prescribing. 1, 2 Guidelines mandate systematic assessment of specific metrics at each stimulant follow-up visit, which are conspicuously absent from this documentation.

Missing Required Monitoring Elements

Vital signs documentation is completely absent. Blood pressure and pulse must be measured and documented at every stimulant follow-up visit 1, 2. This is non-negotiable for amphetamine prescribing, particularly given the patient is on 35 mg total daily dose (30 mg ER + 5 mg IR).

Height and weight measurements are not recorded. 1 These anthropometric measurements should be obtained at minimum monthly during titration and at each visit during maintenance to monitor for growth suppression, a known stimulant adverse effect.

No standardized rating scales were utilized or documented. 1, 3 Guidelines explicitly recommend obtaining ADHD rating scales from both parents and teachers at follow-up visits to objectively assess treatment response. The caregiver's subjective report that medication "seems to be working" is insufficient for controlled substance prescribing documentation.

Inadequate Clinical Assessment

The note fails to document specific target symptoms or quantify improvement. 1 Phrases like "some improvement in focus and impulsivity" lack the specificity required. You should document:

• Baseline symptom severity scores
• Current symptom severity scores
• Percentage improvement in specific domains (inattention, hyperactivity, impulsivity)
• Functional improvement in academic performance (grades, homework completion rates)
• Behavioral incident frequency at school

Medication adherence concerns are mentioned but not addressed. The caregiver reports "ongoing need for reminders to take doses"—this represents a significant adherence problem that requires intervention, not passive documentation. 2 You should document:

• Specific adherence strategies implemented (smartphone alarms, pill organizers, school nurse administration)
• Whether missed doses correlate with behavioral deterioration
• Consideration of once-daily long-acting formulation to improve adherence

"Persistent behavioral concerns at school" is vague and clinically inadequate. 1 Cell phone violations and impulsivity could represent:

• Inadequate stimulant coverage duration (wearing off before end of school day)
• Suboptimal dosing requiring titration
• Oppositional defiant disorder symptoms requiring separate intervention
• ASD-related executive function deficits not responsive to stimulants

The note provides no analysis of whether these behaviors represent ADHD symptoms inadequately controlled by current medication or comorbid ASD features.

Dosing and Regimen Concerns

The current regimen may be suboptimal for this patient's needs. 4 The combination of 30 mg ER morning + 5 mg IR noon suggests:

• The ER formulation is not providing adequate afternoon coverage
• Total daily dose of 35 mg is within FDA-approved range for adolescents (up to 40 mg) 4
• However, the need for a noon booster dose indicates potential for optimization

Consider switching to a single long-acting formulation to address adherence issues and provide more consistent coverage. 2 Options include:

• Increasing the ER dose to 40 mg once daily (eliminating the noon dose that requires reminders)
• Switching to lisdexamfetamine, which provides longer duration of action and may improve adherence
• Adding an afternoon IR dose (4 PM) instead of noon if late-day coverage is needed for homework

ASD-Specific Considerations Ignored

The note fails to address ASD-specific treatment considerations. 5, 6, 7 Research demonstrates that children with ADHD and comorbid ASD:

• Respond similarly to stimulants as children with ADHD alone 6
• May require different side effect monitoring (sleep difficulties are more common) 6
• Often benefit from adjunctive alpha-2 agonists like clonidine for behavioral regulation 2, 5

The clonidine 0.1 mg BID is appropriate as adjunctive therapy for this population 2, 8, but the note should document:

• Whether clonidine is addressing specific ASD-related symptoms (sleep, aggression, emotional dysregulation)
• Blood pressure monitoring for clonidine (separate from stimulant monitoring)
• Whether the combination is providing synergistic benefit

Transition Planning Inadequately Addressed

The mention of "guardianship implications for stimulant prescribing at age of majority" is concerning and legally problematic. At age 18, this patient will have full medical decision-making capacity unless legally adjudicated incompetent. The note should document:

• Current assessment of patient's capacity to manage his own medications
• Education provided to patient (not just caregiver) about ADHD, medication effects, and risks
• Transition planning for independent medication management
• Discussion of controlled substance regulations and diversion risks 9

This is particularly critical given the adherence issues already documented. If the patient cannot remember to take noon doses with parental reminders, how will he manage independently at 18?

Required Documentation for Next Visit

To meet standard of care, your next follow-up note must include:

1. Vital signs: Blood pressure, pulse, height, weight 1, 2

2. Standardized rating scales: ADHD-RS-IV or Conners completed by parent AND teacher 1, 3

3. Specific symptom quantification:

   • Frequency of impulsive behaviors (times per day/week)
   • On-task behavior percentage in classroom
   • Homework completion rate
   • Social functioning assessment

4. Side effect systematic inquiry: 1

   • Appetite (quantify weight change)
   • Sleep (onset latency, total sleep time, quality)
   • Mood (irritability, emotional lability)
   • Cardiovascular symptoms (chest pain, palpitations, syncope)
   • Tics or stereotypies (particularly relevant in ASD)

5. Functional impairment assessment:

   • Academic performance (grades, teacher feedback)
   • Social relationships (peer interactions, family dynamics)
   • Activities of daily living

6. Medication adherence plan:

   • Specific interventions implemented
   • Consideration of regimen simplification

7. Clinical decision-making rationale:

   • Why current dose is continued vs. adjusted
   • Whether behavioral concerns represent medication failure or comorbid symptoms
   • Plan for addressing school behavioral issues (behavioral interventions, school accommodations, medication adjustment)

Medicolegal Risk

This documentation exposes you to significant medicolegal risk. If this patient experiences a cardiovascular event, develops growth suppression, or has medication diversion, your failure to document required monitoring parameters will be indefensible. 1, 9 Controlled substance prescribing requires meticulous documentation demonstrating medical necessity, appropriate monitoring, and clinical decision-making.

The note should be amended immediately to include vital signs from today's visit (if obtained but not documented) or the patient should be called back for this assessment before medications are refilled.